X4 Pharma To Present At Canaccord Genuity’s 36th Annual Growth Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer, today announced that Paula Ragan, PhD, President and Chief Executive Officer, will present at the upcoming Canaccord Genuity 36th Annual Growth Conference in Boston on Thursday, August 11, 2016 at 12:00 p.m. ET.